Organogenesis Holdings Inc. cash flow to debt ratio of -7.76% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Organogenesis Holdings Inc.'s free cash flow has decreased 685.73% from $4.18M last year to $-24.46M, signaling decreasing performance

Organogenesis Holdings Inc.'s debt to equity ratio is 0.23, which means that the company's assets are healthy financed, signaling financial stability.

Organogenesis Holdings Inc.'s debt has increased relative to shareholder equity from 0.11 last year to 0.23 today, signaling weakened financials

Organogenesis Holdings Inc. has a net debt to EBITDA ratio of 0.53x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Organogenesis Holdings Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Organogenesis Holdings Inc.'s profit margin has decreased (11.17K%) in the last year from 0.18% to -19.76%, signaling decreasing performance

Organogenesis Holdings Inc.'s short-term assets of $362.19M exceed its short-term liabilities of $100.12M

Organogenesis Holdings Inc.'s return on assets of -22.20% is lower than the 5.00% threshold, indicating inefficient asset utilization

Organogenesis Holdings Inc.'s return on equity of -24.23%, is lower than 15.00%, indicating bad performance

Organogenesis Holdings Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Organogenesis Holdings Inc. had positive net income in 5 out of 5 years, indicating stable and consistent earnings

Organogenesis Holdings Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Organogenesis Holdings Inc. has negative free cash flow, indicating cash burn

Organogenesis Holdings Inc.'s yearly earnings has increased 4.20K% since last year from $861.00K to $37.03M, signaling increasing performance

Organogenesis Holdings Inc.'s yearly revenue has increased 17.04% since last year from $482.04M to $564.17M, signaling increasing performance

ROIC -8.12% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Organogenesis Holdings Inc.'s 3-year revenue CAGR of 7.68% is positive, indicating growing revenue over the past 3 years

Organogenesis Holdings Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Organogenesis Holdings Inc. had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

Organogenesis Holdings Inc. has insufficient data to evaluate this check.

Organogenesis Holdings Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Organogenesis Holdings Inc. is undervalued relative to its fair value price of 4.23 based on EBITDA multiple model

Organogenesis Holdings Inc. has an EV/EBITDA ratio of 3.77x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Organogenesis Holdings Inc. is undervalued relative to its fair value price of 4.22 based on Earnings Fair Value model

Organogenesis Holdings Inc.'s earnings growth over the measurement period is negative; the PEG ratio is not meaningful and the check fails.

Organogenesis Holdings Inc. has a price-to-book ratio of 0.83x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Organogenesis Holdings Inc. has a price-to-sales ratio of 0.52x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue